Abstract:Abstract Background Enhancer of zesta homologue 2 (EZH2) is an essential component of polycomb repressive complex 2 (PRC2) that contributes to tumor progression and chemo-resistance. The aim of this study was to comprehensively assess the prognostic value of EZH2 across the morphologic and molecular spectra of high-grade serous ovarian carcinoma (HGSOC) by utilizing both immunohistochemistry (IHC) and proteogenomic technologies. Methods IHC of EZH2 was performed using a tissue microarray of 79 HGSOC scored (+/−) for lymphovascular invasion (LVI), tumor-infiltrating lymphocytic aggregates ≥1 mm (TIL) and architectural growth patterns. The association of EZH2 H-score with response to therapy and overall survival was evaluated by tumor features. We also evaluated EZH2 transcriptional (RNA sequencing) and protein (mass spectrometry) expression from bulk tumor samples from 336 HGSOC from The Cancer Genome Atlas (TCGA). EZH2 expression and co-expression networks were compared by clinical outcomes. Results For HGSOC without TIL (58%), EZH2 expression was almost 2-fold higher in platinum resistant tumors (P = 0.01). Conversely, EZH2 was not associated with platinum resistance among TIL+ HGSOC (P = 0.41). EZH2 expression was associated with reduced survival for tumors with LVI (P = 0.04). Analysis of TCGA found higher EZH2 expression in immunoreactive and proliferative tumors (P = 6.7 × 10− 5) although protein levels were similar across molecular subtypes (P = 0.52). Both mRNA and protein levels of EZH2 were lower in platinum resistant tumors although they were not associated with survival. Co-expression analysis revealed EZH2 networks totaling 1049 mRNA and 448 proteins that were exclusive to platinum sensitive or resistant tumors. The EZH2 network in resistant HGSOC included CARM1 which was positively correlated with EZH2 at both mRNA (r = 0.33, p = 0.003) and protein (r = 0.14, P = 0.01) levels. Further, EZH2 co-expression with CARM1 corresponded to a decreased prognostic significance of EZH2 expression in resistant tumors. Conclusions Our findings demonstrate that EZH2 expression varies based on its interactions with immunologic pathways and tumor microenvironment, impacting the prognostic interpretation. The association between high EZH2 expression and platinum resistance in TIL- HGSOC warrants further study of the implications for therapeutic strategies.

EZH2: The roles in targeted therapy and mechanisms of resistance in breast cancer

Morphologic and Molecular Correlates of EZH2 As a Predictor of Platinum Resistance in High-Grade Ovarian Serous Carcinoma.

EZH2-mediated development of therapeutic resistance in cancer

EZH2‐associated tumor malignancy: A prominent target for cancer treatment

EZH2: a novel target for cancer treatment

EZH2-mediated PP2A Inactivation Confers Resistance to HER2-targeted Breast Cancer Therapy

Targeting EZH2 for cancer therapy: From current progress to novel strategies

Treating human cancer by targeting EZH2

Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential

EZH2, a prominent orchestrator of genetic and epigenetic regulation of solid tumor microenvironment and immunotherapy

Targeting EZH2 in Cancer: Mechanisms, Pathways, and Therapeutic Potential

EZH2 Inhibition Sensitizes Tamoxifen‑resistant Breast Cancer Cells Through Cell Cycle Regulation.

Targeting EZH2 to overcome the resistance to immunotherapy in lung cancer

Combined inhibition of PARP and EZH2 for cancer treatment: Current status, opportunities, and challenges

The roles of EZH2 in cancer and its inhibitors

EZH2 inhibition: a promising strategy to prevent cancer immune editing

Preclinical and Basic Research Strategies for Overcoming Resistance to Targeted Therapies in HER2-Positive Breast Cancer

Regulation of Chromosome Regulator EZH2 in Cancer Epigenetics and EZH2 Targeted Drugs in Cancer Therapy

Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells

EZH2 PROTACs target EZH2- and FOXM1-associated oncogenic nodes, suppressing breast cancer cell growth

EZH2: An Accomplice of Gastric Cancer